# Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

> **NCT06495723** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xenothera SAS** · enrollment: 54 (estimated)

## Conditions studied

- Peripheral T Cells Lymphoma (PTCL)

## Interventions

- **DRUG:** LIS1

## Key facts

- **NCT ID:** NCT06495723
- **Lead sponsor:** Xenothera SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06495723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06495723, "Polyspecific Antibodies in Lymphoproliferative T-cell Disorders". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06495723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*